B. Riley lowered the firm’s price target on NGM Biopharmaceuticals to $3.50 from $7.00 and keeps a Buy rating on the shares. The risk-reward is compelling following a recent management post-Q3 earnings catch-up that focused on a major oncology portfolio strategy update anticipated around YE23, the analyst tells investors in a research note. The firm expects the new CFO to further catalyze non-core programs’ externalization.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NGM:
- NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®
- NGM Biopharmaceuticals reports Phase 2b study results from ALPINE 4 trial
- NGM Biopharmaceuticals price target lowered to $4 from $9 at TD Cowen
- NGM Biopharmaceuticals reports Q3 EPS (35c), consensus (42c)
- NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
